search
Back to results

Fascial Therapy in Elbow Hemophilic Arthropathy (HeL-Fascial)

Primary Purpose

Hemophilia

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Experimental group
Sponsored by
Real Fundación Victoria Eugenia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemophilia focused on measuring Hemophilia, Elbow, Arthropathy, Joint pain, Range of motion, Myofascial techniques, Safety patients, Quality of life, Functionality

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with hemophilia A and B
  • Patients adults (over 18 years)
  • Patients diagnosed with hemophilic arthropathy of the elbow (by clinical assessment with the Hemophilia Joint Health Score)
  • Patients pn prophylactic treatment with FVIII / FIX concentrates.

Exclusion Criteria:

  • Patients without ambulation ability
  • Patients with inhibitors
  • Patients with neurological or cognitive alterations that impede the comprehension of the questionnaires and physical tests
  • Patients who have not signed the informed consent document.

Sites / Locations

  • Royal Victoria Eugenia Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Expermiental group

Control group

Arm Description

All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:

Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.

Outcomes

Primary Outcome Measures

Change from baseline elbow joint bleeding frequency after treatment and at 3 months
After the first session of physiotherapy patients will be given a self-register where they can record all the observations they feel (from hematomas or hemarthros, to any other discomfort or perception). Similarly, the principal investigator of the study will monitor all patients within 48 hours after each physical therapy session.

Secondary Outcome Measures

Change from baseline range of motion of elbow after treatment and at 3 months
Change from range of movement of elbow during treatment and follow-up period at 3 months. The range of motion of the elbow joint will be measured using a universal goniometer, using the protocol for measuring joint motion described by Felipe Querol. Measurement instrument: universal goniometer with the protocol to measurement for patients with hemophilia
Change from baseline elbow joint status after treatment and at 3 months
Change from elbow joint status during treatment and follow-up period at 3 months. Measurement instrument: Haemophilia Joint Health Score (scale 0-20).
Change from baseline joint pain of elbow after treatment and at 3 months
Change from joint pain of ankle during treatment and follow-up period at 3 months.The perception of ankle pain will be measured using visual analog scale (scale 0-10).
Change from baseline upper limb functionality after treatment and at 3 months
Change from upper limb functionality during treatment and follow-up period at 3 months. The perception of ankle pain will be measured using DASH Questionnaire. The Spanish version of this scale used internationally will evaluate upper limb functionality.
Change from baseline quality of life after treatment and at 3 months
Change from quality of life during treatment and follow-up period at 3 months. The quality of life perception will be measured using SF-36 Questionnaire. This scale will assess the perception of quality of life of patients included in the study.

Full Information

First Posted
December 30, 2016
Last Updated
February 25, 2019
Sponsor
Real Fundación Victoria Eugenia
search

1. Study Identification

Unique Protocol Identification Number
NCT03009591
Brief Title
Fascial Therapy in Elbow Hemophilic Arthropathy
Acronym
HeL-Fascial
Official Title
Prospective and Multicenter Study to Assess the Safety and Effectiveness of a Physiotherapy Treatment Through Fascial Therapy in Hemophilic Elbow Arthropathy. A Pilot Study.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
February 12, 2018 (Actual)
Primary Completion Date
December 1, 2018 (Actual)
Study Completion Date
February 15, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Real Fundación Victoria Eugenia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Introduction: The common clinical manifestations of hemophilia are skeletal muscle bleeds, especially hematomas and hemarthrosis. Repeated episodes of joint bleeding in certain joints, causing a progressive joint deterioration. Secondary disorders to this joint degeneration include: biomechanical alterations, loss of range of movement and periarticular muscle atrophy. Design. A prospective, multicenter and longitudinal pilot study to evaluate the efficacy of a treatment protocol with fascial therapy applied in patients with hemophilic arthropathy of the elbow. Aimed: To evaluate the safety and efficacy of a physiotherapy treatment by fascial therapy in patients with hemophilic arthropathy of the elbow Patients: A total of 60 patients with hemophilia and prophylactic treatment will be recruited for inclusion in the study. Patients will be recruited in 6 centers, from different regions of Spain. Intervention: Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally: Measuring instruments and study variables: goniometric evaluation (range of movement); visual analog scale (joint pain); Haemophilia Joint Health Score (joint status); DASH Questionnaire (functionality of upper limbs); SF-36 Questionnaire (perception of quality of life). At the same time, the study will allow to determine joint bleeding caused by applied physiotherapy treatment. Expected results: First, it is intended to demonstrate the safety of this physiotherapy technique in patients with hemophilia. Likewise, an improvement in the perception of elbow pain and joint mobility is expected. An improved functionality of the upper limb is also foreseen and with it, an enhanced perception of quality of life of these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia
Keywords
Hemophilia, Elbow, Arthropathy, Joint pain, Range of motion, Myofascial techniques, Safety patients, Quality of life, Functionality

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
69 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Expermiental group
Arm Type
Experimental
Arm Description
All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
Intervention Type
Other
Intervention Name(s)
Experimental group
Other Intervention Name(s)
Fascial therapy group
Intervention Description
Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes. Transverse sliding of the flexor muscles of the wrist and fingers. Transverse sliding for the biceps brachii muscle. Longitudinal surface sliding over the superficial fascia in the posterior arm region. Transverse sliding over the brachial triceps tendon. Transverse sliding for the pectoralis major muscle. Transverse sliding for the posterior axillary region pectoralis major muscle. Induction of the posterior axillary fold. Induction (crossed hands over the brachial region and forearm). Maneuver of transverse planes for the cervicothoracic region. Upper limb telescopic maneuver.
Primary Outcome Measure Information:
Title
Change from baseline elbow joint bleeding frequency after treatment and at 3 months
Description
After the first session of physiotherapy patients will be given a self-register where they can record all the observations they feel (from hematomas or hemarthros, to any other discomfort or perception). Similarly, the principal investigator of the study will monitor all patients within 48 hours after each physical therapy session.
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit
Secondary Outcome Measure Information:
Title
Change from baseline range of motion of elbow after treatment and at 3 months
Description
Change from range of movement of elbow during treatment and follow-up period at 3 months. The range of motion of the elbow joint will be measured using a universal goniometer, using the protocol for measuring joint motion described by Felipe Querol. Measurement instrument: universal goniometer with the protocol to measurement for patients with hemophilia
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit
Title
Change from baseline elbow joint status after treatment and at 3 months
Description
Change from elbow joint status during treatment and follow-up period at 3 months. Measurement instrument: Haemophilia Joint Health Score (scale 0-20).
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit
Title
Change from baseline joint pain of elbow after treatment and at 3 months
Description
Change from joint pain of ankle during treatment and follow-up period at 3 months.The perception of ankle pain will be measured using visual analog scale (scale 0-10).
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit
Title
Change from baseline upper limb functionality after treatment and at 3 months
Description
Change from upper limb functionality during treatment and follow-up period at 3 months. The perception of ankle pain will be measured using DASH Questionnaire. The Spanish version of this scale used internationally will evaluate upper limb functionality.
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit
Title
Change from baseline quality of life after treatment and at 3 months
Description
Change from quality of life during treatment and follow-up period at 3 months. The quality of life perception will be measured using SF-36 Questionnaire. This scale will assess the perception of quality of life of patients included in the study.
Time Frame
Screening visit, within the first seven days after treatment and after three months follow-up visit

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with hemophilia A and B Patients adults (over 18 years) Patients diagnosed with hemophilic arthropathy of the elbow (by clinical assessment with the Hemophilia Joint Health Score) Patients pn prophylactic treatment with FVIII / FIX concentrates. Exclusion Criteria: Patients without ambulation ability Patients with inhibitors Patients with neurological or cognitive alterations that impede the comprehension of the questionnaires and physical tests Patients who have not signed the informed consent document.
Facility Information:
Facility Name
Royal Victoria Eugenia Foundation
City
Madrid
State/Province
Madird
ZIP/Postal Code
28029
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35081366
Citation
Cuesta-Barriuso R, Merono-Gallut J, Donoso-Ubeda E, Lopez-Pina JA, Perez-Llanes R. Effect of a Fascial Therapy Treatment on Quality of Life in Patients With Hemophilic Elbow Arthropathy: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2022 May;103(5):867-874. doi: 10.1016/j.apmr.2021.12.023. Epub 2022 Jan 23.
Results Reference
derived
PubMed Identifier
33684015
Citation
Cuesta-Barriuso R, Perez-Llanes R, Lopez-Pina JA, Donoso-Ubeda E, Merono-Gallut J. Manual therapy reduces the frequency of clinical hemarthrosis and improves range of motion and perceived disability in patients with hemophilic elbow arthropathy. A randomized, single-blind, clinical trial. Disabil Rehabil. 2022 Jul;44(15):3938-3945. doi: 10.1080/09638288.2021.1894607. Epub 2021 Mar 8.
Results Reference
derived

Learn more about this trial

Fascial Therapy in Elbow Hemophilic Arthropathy

We'll reach out to this number within 24 hrs